Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Arcus Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Arcus Biosciences, Inc.

RCUS

Arcus Biosciences, Inc.

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapies for cancer treatment. Its portfolio includes small molecules and antibodies targeting immune checkpoints and cancer cell pathways, such as TIGIT, PD-1, and adenosine receptors. Arcus focuses on combination therapies for lung, gastrointestinal, renal, and other cancers, collaborating with partners like Gilead for development and commercialization, while leveraging third-party manufacturing and strategic licensing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Arcus Biosciences, Inc.

1
1
Arcus Biosciences, Inc. Arcus Biosciences Reports $128 Million Net Loss in Q1 2026, Revenue Declines 39%

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Arcus Biosciences, Inc. Arcus Biosciences Reports $353 Million Net Loss and Strategic Updates in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Arcus Biosciences, Inc. Arcus Biosciences Reports $135 Million Net Loss in Q3 2025, Revenue Declines 46%

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Arcus Biosciences, Inc. Arcus Biosciences Reports $160M Revenue in Q2 2025, Driven by License Revenue

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Arcus Biosciences, Inc. Arcus Biosciences Reports Significant Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Arcus Biosciences, Inc. Arcus Biosciences Reports 50% Revenue Growth, Strategic Partnerships in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments